Empagliflozin benefits acute HF regardless of baseline impairment: EMPULSE - Healio

4/7/2022 12:00:00 AM3 years 10 months ago

WASHINGTON — Patients with acute HF assigned the SGLT2 inhibitor empagliflozin saw a greater improvement in HF symptoms, physical limitations and quality of life measures vs. placebo, with benefit seen as early as 15 days, data show.Presenting new analy…

Source/Disclosures Source: Kosiborod M, et al. Featured Clinical Research III. Presented at: American College of Cardiology Scientific Session; April 2-4, 2022; Washington, D.C. (hybrid meeting). … [+5042 chars]

full article...

Empagliflozin benefits acute HF regardless of baseline impairment: EMPULSE - Healio

WASHINGTON &mdash; Patients with acute HF assigned the SGLT2 inhibitor empagliflozin saw a greater improvement in HF symptoms, physical limitations and quality of life measures vs. placebo, with benefit seen as early as 15 days, data show.Presenting new analy…

WASHINGTON — Patients with acute HF assigned the SGLT2 inhibitor empagliflozin saw a greater improvement in HF symptoms, physical limitations and quality of life measures vs. placebo, with benefit seen as early as 15 days, data show.Presenting new analy…